Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer

Prognosis for regionally advanced non-small cell lung cancer (NSCLC) patients is poor. Treatment with either surgery or radiation has been unsatisfactory and 5 years survival rates of less than 10 % are reported for these patients [1]. In an attempt to increase the complete resection and survival rates in stage IIIA disease, several pilot studies have explored multiple therapeutic modalities including Neo-Adjuvant chemotherapy or concomitant chemotherapy and radiotherapy [2, 3, 4].